The present invention relates to novel glycerin ether ethoxylate solfactant compounds, compositions employing the same, and methods of using these compounds. Beneficially the compounds have efficacy as both solvents and surfactants with low foam and low viscosity. The compounds of the present invention can be used as antimicrobials and/or sanitizing agents in various formulations. The compounds of the present invention are also suitable for use as solvents and/or hydrotropes.

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.

The invention provides compound of the general formula: ##STR00001##
in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either CH.(CH.sub.2L).sub.2 or C(CH.sub.2L)(CH.sub.2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.

The present invention relates to the field of drug carrier systems and polymer therapeutics and diagnostics. It provides derivatized unimolecular polyols with a hydrophobic core moiety and a polyanionic, preferably, sulfated hydrophilic shell, N in particular to unimolecular hyperbranched sulfated polyglycerol micelles having a hydrophilic shell and a hydophrobic core. These may be used for the supramolecular encapsulation and transport of hydrophobic guest molecules into biological systems. The micelles can be applied as a drug carrier system for therapy and for diagnosis. They may also be therapeutic agents on their own. The invention also relates to preparation of said micelles.

Embodiments of the present disclosure are directed towards functionalized oligomers. As an example, a functionalized oligomer can be represented of Formula (I): (Formula I) in which R.sup.1 is a structure of Formula II: (Formula II) and R.sup.2 has a formula CxHyO, wherein n is an integer having a value from 2 to 6, m is an integer having a value from 2 to 10, X independently is an integer having a value from 1 to 12, and Y is an integer having a value from 2 to 24. ##STR00001##

The present invention relates to esterified glycerylated alkyl glycoside and to a process for making same. The esterified glycerylated alkyl glycoside have one or more polyglyceryl moieties and one or more acyl moieties, wherein all of the one or more acyl moieties are situated on the one or more polyglyceryl moieties via an ester linkage. These compounds have been found to be useful as emulsifiers and coemulsifiers in the formulation of a phase stable emulsions suitable for use in personal care, home care, industrial and institutional, and health care applications.

The present invention discloses a non-linear PEGylated lipid, including the structure represented by the Formula (1); wherein, B.sub.1 and B.sub.2 are linking bonds or alkylene groups; L.sub.1 and L.sub.2 are linking bonds or divalent linking groups; L.sub.x, Y, and L.sub.d are divalent linking groups; R.sub.1 and R.sub.2 are C.sub.4-50 hydrocarbon groups or C.sub.4-50 residues of hydrocarbon derivative containing 1-4 heteroatoms; X is CH< or

##STR00001##

n.sub.1, n.sub.2, and n.sub.3 are integers in the range of 4-250; T is a terminal group. Compared with linear PEGylated lipids, the non-linear PEGylated lipid provided herein can realize better protective effects toward the modified LNPs. The lipid pharmaceutical composition of the present invention exhibits high efficiency of drug encapsulation, appropriate particle size, non-toxicity, and good stability in serum. The LNP-nucleic acid pharmaceutical composition of the present invention demonstrates an excellent ability to complex with nucleic acids and shows high transfection activity.

##STR00002##

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

It is provided a method of treatment of a human or animal patient in need thereof to achieve a reduction of the viscosity of mucus of the patient which is carried out by administering a polyglycerol derivative having a linear or dendritic polyglycerol backbone and carrying at least one thiol group covalently bound to the polyglycerol backbone. It is further provided a method of treatment of a human or animal patient suffering from chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, bronchiectasis, chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea by administering a polyglycerol derivative. Further specific thiol-functionalized polyglycerol derivatives and a corresponding manufacturing method are provided.